Baffler
08 Jul 2015
Edison ups value to 48p New note out from Edison and they now have a 48p per share value on Allergy Therapeutics.Valuation: DCF valuation of £260mAdding US value across the three PQ indications to a European base valuation of£88m results in a valuation of £260m or 48p per share compared to a previous EUvaluation range of £96-129m plus indicative US value up to £46m for PQ Grass andRagweed. Potential catalysts include further news on the commercial ordevelopment strategy.This time next year Rodney!PS; You can subscribe for free to Edison's research notes.
d gaser
06 Jul 2015
Positive Dust Mite Study Results 06 Jul 2015 07
0:18Allergy Therapeutics RNS Number : 2061SAllergy Therapeutics PLC06 July 2015 6 July 2015 Allergy Therapeutics plc("Allergy Therapeutics" or "the Company"
Positive Dust Mite Study Results Allergy Therapeutics, the fully integrated specialty pharmaceutical company specialising in allergy vaccines, today announces positive results from its prospective observational Acarovac Plus clinical study for the treatment of house dust mite allergy. Acarovac Plus is being developed as one of the Company's new generation of products to address the perennial allergy market with innovative and short-course therapies. At the Adjuvants in Allergy conference over the past weekend, Dr. Albert Roger, Director of the Allergy Unit at Universitari Hospital Germans Trias Pujol, Badalona Spain, presented the results of a prospective observational one-year follow-up study, comparing the safety, tolerability and long-term effectiveness of Acarovac Plus using Dermatophagoides pteronyssinus (house dust mite) in 30 adult patients with allergic rhinitis and/or asthma. Acarovac Plus has been designed to administer maintenance doses every 6-8 weeks, reducing the number of annual injections required and providing a natural, biodegradable, alternative depot1 vaccine. Tolerability of Acarovac Plus was demonstrated with no reported adverse events. The effectiveness of Acarovac Plus was measured in patients using a nasal provocation test, which evaluates the sensitivity of each patient to mite allergens. Nasal airway assessments were performed using peak nasal inspiratory flow measurements. In summary, a reduction in symptom scores of >50% were observed during follow up visits after one year. Immunological markers were also assessed and showed significant improvements in antibody IgG4 and anti-inflammatory IL-10 molecules, indicating tolerance induction in patients after one year of treatment. A validated patient satisfaction survey provided information that was reflective of the clinical findings from the study. A high degree of overall patient satisfaction was observed, which encompassed significant improvements in scores after one year in relation to overall effectiveness and convenience of the treatment. This reinforces one of the main objectives of Allergy Therapeutics in improving patient life by producing effective treatments, while at the same time reducing the discomfort of injections, improving compliance and adherence of allergy immunotherapy products. Further to the efficacy noted for Acarovac Plus2, Allergy Therapeutics is developing Acarovac Quattro, an ultra-short course therapy utilising the adjuvant monophosphoryl lipid A (MPL), which is used in the Company's successful Pollinex Quattro product range currently in late stage development in Europe and the US. Dr Roger, principal investigator for the study, said:"The successful clinical results in the one year follow-up study clearly demonstrate the effective treatment of house dust mite allergy by Acarovac Plus. We also observed significant decreases in symptom scores and improvement in nasal sensitivity immediately after the up dosing phase of one month. Acarovac Plus therapy not only led to a high rate of patient satisfaction early in treatment, but also the convenient maintenance regime of injections every 6 weeks has the potential to improve the adherence and compliance with the vaccine regime that is essential for a successful treatment."
the wise owl
03 Jul 2015
Re: CFR sold to Abbott for $2.9billion As I understand it ,by looking at the placing documents the Weinstocks now only control about 1%.Abbott have 44%,Odey 7%,Invesco 5.6%,Southern Fox 23%(all approx figures).Altogether about 80% are in firm hands.For me AGY is a defacto subsiduary of Abbott exploring one niche market and making money. I hope that one day Abbott will tidy up and my reading of the situation is that the institutional shareholders share my view. Southern Fox endeavour to maintain their % by market purchases.I keep looking at the market cap of Circassia and dream!!
d gaser
03 Jul 2015
Re: CFR sold to Abbott for $2.9billion Sorry everyone, but the bit of my last post of yesterday where it said " which I believe they owned" was in fact a mistake and should not have been left in, In fact I thought I had removed it, sorry about that . CFR Pharmaceuticals S.A was in fact traded on the Santiago Exchange .see link www.bloomberg.com/news/articles/2014-05-16/abbott-agrees-to-purchase-chile-s-cfr-pharmaceutical
d gaser
02 Jul 2015
CFR sold to Abbott for $2.9billion This is an Interesting story regarding the main stockholders of AGY, plus members of our Board. It appears that CFR Pharmaceutical SA, which I believe they owned was sold to Abbott last year, for $2.9 billion .The three controllers of that company were Alejandro Weinstein Crenovich, CFR’s chairman, Alejandro Weinstein Manieu was its chief executive officer, and Nicolas Weinstein Manieu ,also sat on their board. Weinstein Crenovich, the chairman is the son of the founder. The other two are Weinstein Crenovich’s sons apparently . The Weinstocks I believe are our biggest stock holders at the moment, and have recently raised even more cash here in the UK, in order to facilitate further trials of Polynex in the US .There's also an Interesting note in the CFR accounts, regarding AGY.Doe’s anybody know what this means ?BE HAPPYDAVE CFR PHARMACEUTICALS AND SUBSIDIARIESNotes to the Interim Consolidated Financial StatementsFor the period ended March 31, 2014(3) Significant Accounting PoliciesThe accounting policies set out below have been applied consistently to all of the periods shown in theseinterim consolidated financial statements and they have been applied consistently by the Group’s entities.(a) Investments in subsidiaries (combinations of businesses)Combinations of businesses are booked using the purchase method. This involves booking the identifiableassets (including previously non-booked intangible assets) and liabilities (including contingent liabilitiesand excluding future restructurings) of the business acquired at fair value.(b) Investments in associatesThe Company and its subsidiaries value their investments in associates using the equity method. Anassociate is an entity in which the Company has significant influence but not control, and nor is a jointventure. Under this method, the investment is shown in the statement of financial position at cost plussubsequent changes to the acquisition proportionally to the equity of the associate, by using thepercentage holding in the associate. The associated goodwill is included in the book value of theinvestment and is not amortized. The charge or credit to results reflects the proportion of the associate'sresults.Changes in the equity of the associates are booked proportionately as a charge or credit to equity andclassified according to their origin, and, if applicable, they are disclosed in the statement of changes inequity.The reporting dates of the associate and CFR Pharmaceuticals S.A. and the accounting policies are similarfor equivalent transactions and events under similar circumstances, with the exception of AllergyTherapeutics PLC whose financial statements considered for the proportional equity method are as ofDecember 31, 2013 for the statement of financial position and for three months ended December 31, 2013for the statement of comprehensive results.If significant influence is lost or the investment is sold or is made available for sale, the equity method isdiscontinued, thus suspending the booking of proportional results.see accounts section www.cfr-corp.com/?lang=en
d gaser
17 Mar 2015
.Proposed Placing and section 9 consort party rules Re Proposed Placing and Notice of General Meeting.After reading this notice, I have been somewhat confused with regard to the section of this notice called Related Party Transaction and the next section, called Convertible Loan Notes. Both sections are below the figures so you have to scroll down about two thirds of the way.Both sections talks about a buy out under section 9 of the takeover code.Is there anybody here with knowledge of this ,and who can put this section of the document into plain English, please ?BE HAPPYDAVE See www.iii.co.uk/research/LSE:AGY/news/item/1410095/issue-equity?context=LSE:AGY
Baffler
17 Mar 2015
Re: will the Euro crash affect AGY income ?.... Which is why institutions were happy to part with £20million.
d gaser
16 Mar 2015
will the Euro crash affect AGY income ?.. As our main market is Europe, can any body tell us how this company would be affected if Euro crash's? .At the moment I understand most of our products are priced in pound sterling, but our biggest market pays in Euros, I also understand from previous notices that when Euro's are converted back into pounds, it affects our mark ups and costs, as we loss money during the conversion process if the Euro has fallen against the pound if a set contract has been agreed between the company ,and a European company or government department .Has Any body got a view on this problem, as it seems that if Greece leaves the Euro , then it's highly likely they will go bankrupt, and return to their old currency ? obviously this will affect the rest of Europe and will probably course further falls in the Euro with in the European Union, which as we all know is our main market right now . BE HAPPYDAVE
d gaser
10 Mar 2015
Allergy Therapeutics has raised £20.0m Allergy Therapeutics has raised £20.0m,and issued 94,117,650 new ordinary shares .At the moment, nobody knows who has purchased the shares, but it could be just those who are part of the consort party as they don't say new investors but they do say the net proceeds of the Placing will be used to fund the clinical development of their lead product, Pollinexâ Quattro Grass through to a BLA and to obtain FDA regulatory approval in the US. In view of this can we now take it AGY were unable to get any US company to join them in taking this product forward, or to get help in getting this product in to stage 1 trials, in the USA, if that is so, then its very disappointing, and seems to back up what George _141 had to say, regarding the problems we face in the USA, regarding differences between European allergists, and their US counterparts, and insurance companies' policies this will I'm afraid make the US market harder to crack . I just hope the European market can sustain the company growth through increased market share, or through increased mark ups ,if not ,then we could find this trial will eat up all the 20m plus our reserves by 2019 which is the date they hope to get FDA approval . That still means by the time AGY get marketing approval act ,we could still be looking to 2020 /21 to see a return on this cash .BE HAPPYDAVE
george_141
24 Feb 2015
Re: Pattern life could it be the problem I do not think patent life is a huge problem, as patents can very often get extensions added on- this is quite a normal thing for a patent attorney worth their salt to "tack on". Also, the second adjuvant in the formulation of PQ is MPL, which is a biological product sourced from GSK. So GSK would have the whip hand in supplying anyone else with MPL.A fundamental issue with PQ in the USA is that there are only 4 shots, which means less business (= profit) for an allergist. For most of the rest of the world, it's a great advantage. Also, it's not a mixture of allergens, which US allergists often prefer (but not so for many European allergists). I think there is plenty of sales opportunity in Europe for a profitable AGY. George
d gaser
22 Jan 2015
Pattern life could it be the problem Can any body tell me when the patterns runs out on Pollinex® Quattro ? or when our product was suspended by the FDA ,I have been looking back over the RNS on here, and on their web site, but they only go back to 2010 ,but I did find a paper on AGY web site, called, Excellence in allergy treatment ,and dated Directory 2007/08. In that article it states. Intellectual property rights to five patent families with further rights to the use of MPL® in new formulations. Patent protection for new products extends to the years 2018-20. If this date is correct ,then that means there is between 3 and 5 years pattern life left ,which is of little help to any company looking for someone to help pay for FDA approval in the states. This might explain why AGY are having problems getting a US backer, in order to take this product through FDA approval, as hospitals act in the states only back full term patent drugs of 10-15 years pattern life has any body else got a view on this ?.www.allergytherapeutics.com/uploads/Allergy%20Therapies_profile.pdf look at the blue section on the right hand side ,third paragraph down Be Happy Dav
